

**India Antimalarial Drugs Market, By Drug Class (Aryl aminoalcohol compounds, Antifolate compounds, Artemisinin compounds, Others), By Mechanism of Action (Treatment for Malaria, Prevention from Malaria), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, Competition, Forecast & Opportunities, 2020-2030F**

Market Report | 2024-10-04 | 87 pages | TechSci Research

**AVAILABLE LICENSES:**

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

**Report description:**

India Antimalarial Drugs Market was valued at USD 30.15 million in 2024 and is anticipated to reach USD 38.82 Million by 2030, with a CAGR of 4.26% during 2025-2030. The antimalarial drugs market in India represents a significant segment within the broader pharmaceutical industry, largely due to the country's historical and ongoing battle with malaria. Government initiatives, increased healthcare expenditure, and heightened awareness of malaria prevention and treatment. Enhanced collaboration between government entities, the private sector, and international organizations is crucial for addressing malaria more effectively. Public-private partnerships are particularly vital for improving drug distribution networks and healthcare infrastructure. Challenges such as drug resistance and supply chain issues must be addressed to ensure sustained progress. The future outlook remains optimistic, supported by ongoing research and development, technological advancements, and collaborative efforts aimed at effectively combating malaria.

**Key Market Drivers**

**Increasing Healthcare Expenditure**

Higher healthcare expenditure allows for improved infrastructure, including healthcare facilities and distribution networks. This enables better access to antimalarial drugs in both urban and rural areas, addressing gaps in availability and affordability. Increased funding facilitates research into new antimalarial treatments and technologies. This leads to the development of more effective drugs and diagnostic tools, enhancing the overall efficacy of malaria management. Greater financial resources support the expansion of healthcare services focused on malaria prevention, diagnosis, and treatment. This includes training healthcare

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

professionals, establishing diagnostic centers, and ensuring adequate supply chains for antimalarial drugs. Collaboration between government agencies, pharmaceutical companies, and non-profit organizations is bolstered by increased healthcare spending. These partnerships drive innovation, improve healthcare delivery, and promote sustainable solutions for combating malaria. Higher expenditure allows for the implementation of quality assurance measures across the supply chain. This ensures that antimalarial drugs meet regulatory standards, reducing the risk of counterfeit medications and enhancing patient safety. Investments in healthcare infrastructure, such as hospitals, clinics, and pharmacies, create a conducive environment for the distribution and administration of antimalarial drugs. This infrastructure development supports comprehensive healthcare services and contributes to overall market growth. Increasing healthcare expenditure in India plays a critical role in advancing the antimalarial drugs market by fostering innovation, improving accessibility, and enhancing the quality of care for malaria patients across the country.

#### Awareness and Education Campaigns

Effective campaigns raise public awareness about the risks of malaria and the importance of timely treatment. This heightened awareness encourages individuals to seek preventive measures and prompt medical assistance, thereby increasing the demand for antimalarial drugs. Education initiatives promote behavioral changes such as using insecticide-treated bed nets, seeking early diagnosis, and completing treatment courses. These changes reduce the incidence of malaria and contribute to sustained demand for antimalarial drugs as part of comprehensive healthcare strategies.

Campaigns also target healthcare professionals, enhancing their knowledge of malaria prevention, diagnosis, and treatment. This training improves the quality of healthcare delivery, ensuring accurate diagnosis and appropriate prescription of antimalarial drugs based on updated guidelines. Localized campaigns empower communities to actively participate in malaria control efforts. This may include community health workers disseminating information, conducting outreach programs, and facilitating access to antimalarial drugs in remote or underserved areas. Partnerships between government agencies, healthcare providers, pharmaceutical companies, and non-governmental organizations (NGOs) strengthen campaign effectiveness. These collaborations amplify messages, leverage resources, and enhance the reach of educational initiatives across diverse demographic groups. Successful awareness campaigns can influence policy-makers to prioritize malaria control programs and allocate resources for healthcare infrastructure development, including the procurement and distribution of antimalarial drugs. Campaigns incorporate monitoring and evaluation frameworks to assess impact metrics such as knowledge levels, behavioral changes, and malaria incidence rates. Data-driven insights guide ongoing improvements in campaign strategies and optimize resource allocation for sustained market growth. Awareness and education campaigns serve as catalysts for growth in the India Antimalarial Drugs Market by increasing demand, promoting behavioral change, empowering communities, fostering collaborations, advocating for policy support, and facilitating continuous monitoring and evaluation of malaria control efforts. These initiatives contribute to a holistic approach towards malaria prevention and treatment, driving market expansion and improving healthcare outcomes nationwide.

#### Key Market Challenges

##### Drug Resistance

The emergence and spread of drug-resistant malaria strains, particularly to traditional treatments like chloroquine and even some artemisinin-based therapies, pose a critical challenge.

Limited treatment options led to decreased efficacy of existing drugs, higher treatment failure rates, prolonged illness, and increased healthcare costs. Addressing drug resistance requires continuous research and development efforts to discover new drugs and therapeutic combinations that remain effective against evolving malaria parasites.

##### Supply Chain Issues

Inefficient supply chain management and logistical challenges in drug distribution, particularly in remote and underserved areas, hinder timely access to antimalarial drugs. Stockouts, expired medications, and inconsistent availability undermine treatment outcomes and weaken efforts to control malaria transmission.

Improving supply chain infrastructure, including cold chain management for drug storage and transportation, is crucial. It requires collaboration between government agencies, pharmaceutical companies, and logistics providers to ensure reliable drug supply to all regions.

##### Public Awareness and Education

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Limited awareness and misconceptions about malaria prevention, symptoms, and treatment options among the general population and healthcare providers. Delayed diagnosis, inadequate treatment adherence, and incomplete treatment courses contribute to higher malaria incidence and prevalence rates.

Effective public health campaigns and targeted educational initiatives are essential to promote early detection, encourage preventive measures like insecticide-treated bed nets, and ensure compliance with treatment protocols. Increasing health literacy empowers communities to actively participate in malaria control efforts and supports sustainable reduction in disease burden.

#### Key Market Trends

##### Advancements in Drug Development and Treatment Innovation

Ongoing research and development efforts are expected to yield new antimalarial drugs and innovative treatment modalities. These advancements aim to overcome drug resistance, enhance treatment efficacy, and reduce side effects, thereby expanding the market with more effective therapeutic options.

Pharmaceutical companies investing in novel drug formulations and combinations will play a crucial role. Collaborative efforts between academia, government institutions, and private sector entities will drive innovation in this space.

##### Technological Integration in Healthcare Delivery

Increasing adoption of digital health technologies, telemedicine, and mobile health applications. These technologies improve access to healthcare services, facilitate remote consultations, enhance patient monitoring, and support adherence to treatment regimens.

Digital platforms will play a vital role in expanding the reach of antimalarial drugs to remote and underserved populations. Integration of data analytics and artificial intelligence (AI) will optimize disease surveillance, aid in early detection, and improve decision-making in malaria control programs.

#### Segmental Insights

##### Drug Class Insights

Based on the category of Drug Class, the Artemisinin compounds segment emerged as the dominant in the market for India Antimalarial Drugs Market in 2024. Artemisinin and its derivatives, known as Artemisinin-based Combination Therapies (ACTs), are endorsed by the World Health Organization (WHO) and Indian health authorities as the preferred first-line treatment for uncomplicated malaria due to their superior efficacy in swiftly clearing parasites from the bloodstream. This policy support is reinforced by government protocols favoring ACTs for their effectiveness in managing resistance and their wide availability through diverse distribution channels, including public health initiatives and private pharmacies. Ongoing research investments aim to enhance the safety and efficacy of Artemisinin derivatives, fostering continuous innovation in malaria treatment strategies. These factors are expected to drive the growth of this segment.

##### Regional Insights

North India emerged as the dominant in the India Antimalarial Drugs Market in 2024, holding the largest market share in terms of both value and volume. North India, particularly states like Uttar Pradesh, Bihar, Rajasthan, and Jharkhand, experiences a higher burden of malaria compared to other regions. This is attributed to factors such as climatic conditions conducive to mosquito breeding and socio-economic factors impacting healthcare access.

The prevalence of malaria drives higher demand for antimalarial drugs in North India, making it a focal point for pharmaceutical companies and healthcare providers. National and state-level malaria control programs prioritize North India due to its significant disease burden. Initiatives like the National Vector Borne Disease Control Programme (NVBDCP) focus on improving malaria diagnosis, treatment, and prevention strategies in these states. Government policies and funding allocations support the procurement and distribution of antimalarial drugs in North India, ensuring accessibility and affordability for affected populations. North India boasts a mix of urban centers and rural areas where healthcare infrastructure, including hospitals, clinics, and pharmacies, facilitates the distribution of antimalarial drugs. Both public health institutions and private healthcare providers play crucial roles in delivering antimalarial treatments across the region, enhancing accessibility for diverse population segments. Collaborative efforts between research institutions, pharmaceutical companies, and government bodies in North India drive innovation in antimalarial drug development. The region serves as a hub for clinical research aimed at improving treatment efficacy, developing new drug formulations, and addressing challenges like drug resistance.

#### Key Market Players

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- ☐☐Cipla Ltd
- ☐☐Sun Pharmaceutical Industries Ltd
- ☐☐Glenmark Pharmaceuticals Ltd
- ☐☐Strides Pharma Science Ltd
- ☐☐Ipca Laboratories Ltd
- ☐☐Aurobindo Pharma Ltd
- ☐☐Alkem Laboratories Ltd
- ☐☐Novartis India Ltd
- ☐☐Lupin Limited
- ☐☐Cadila Healthcare Ltd

**Report Scope:**

In this report, the India Antimalarial Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

☐☐India Antimalarial Drugs Market, By Drug Class:

- o Aryl aminoalcohol compounds
- o Antifolate compounds
- o Artemisinin compounds
- o Others

☐☐India Antimalarial Drugs Market, By Mechanism of Action:

- o Treatment for Malaria
- o Prevention from Malaria

☐☐India Antimalarial Drugs Market, By Distribution Channel:

- o Hospital Pharmacy
- o Retail Pharmacy
- o Online Pharmacy

☐☐India Antimalarial Drugs Market, By Region:

- o North India
- o South India
- o East India
- o West India

**Competitive Landscape**

Company Profiles: Detailed analysis of the major companies presents in the India Antimalarial Drugs Market.

**Available Customizations:**

India Antimalarial Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

**Company Information**

- ☐☐Detailed analysis and profiling of additional market players (up to five).

**Table of Contents:**

1. Product Overview
  - 1.1. Market Definition
  - 1.2. Scope of the Market
    - 1.2.1. Markets Covered
    - 1.2.2. Years Considered for Study
    - 1.2.3. Key Market Segmentations
2. Research Methodology
  - 2.1. Objective of the Study

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
- 3. Executive Summary
  - 3.1. Overview of the Market
  - 3.2. Overview of Key Market Segmentations
  - 3.3. Overview of Key Market Players
  - 3.4. Overview of Key Regions/Countries
  - 3.5. Overview of Market Drivers, Challenges, Trends
- 4. Voice of Customer
- 5. India Antimalarial Drugs Market Outlook
  - 5.1. Market Size & Forecast
    - 5.1.1. By Value
  - 5.2. Market Share & Forecast
    - 5.2.1. By Drug Class (Aryl aminoalcohol compounds, Antifolate compounds, Artemisinin compounds, Others)
    - 5.2.2. By Mechanism of Action (Treatment for Malaria, Prevention from Malaria)
    - 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    - 5.2.4. By Region
    - 5.2.5. By Company (2024)
  - 5.3. Market Map
- 6. North India Antimalarial Drugs Market Outlook
  - 6.1. Market Size & Forecast
    - 6.1.1. By Value
  - 6.2. Market Share & Forecast
    - 6.2.1. By Drug Class
    - 6.2.2. By Mechanism of Action
    - 6.2.3. By Distribution Channel
- 7. South India Antimalarial Drugs Market Outlook
  - 7.1. Market Size & Forecast
    - 7.1.1. By Value
  - 7.2. Market Share & Forecast
    - 7.2.1. By Drug Class
    - 7.2.2. By Mechanism of Action
    - 7.2.3. By Distribution Channel
- 8. East India Antimalarial Drugs Market Outlook
  - 8.1. Market Size & Forecast
    - 8.1.1. By Value
  - 8.2. Market Share & Forecast
    - 8.2.1. By Drug Class
    - 8.2.2. By Mechanism of Action
    - 8.2.3. By Distribution Channel
- 9. West India Antimalarial Drugs Market Outlook
  - 9.1. Market Size & Forecast
    - 9.1.1. By Value

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.2. Market Share & Forecast
  - 9.2.1. By Drug Class
  - 9.2.2. By Mechanism of Action
  - 9.2.3. By Distribution Channel
- 10. Market Dynamics
  - 10.1. Drivers
  - 10.2. Challenges
- 11. Market Trends & Developments
  - 11.1. Recent Developments
  - 11.2. Product Launches
  - 11.3. Mergers & Acquisitions
- 12. India Antimalarial Drugs Market: SWOT Analysis
- 13. Competitive Landscape
  - 13.1. Cipla Ltd
    - 13.1.1. Business Overview
    - 13.1.2. Product & Service Offerings
    - 13.1.3. Recent Developments
    - 13.1.4. Key Personnel
    - 13.1.5. SWOT Analysis
    - 13.1.6. Financials (If Listed)
  - 13.2. Sun Pharmaceutical Industries Ltd
  - 13.3. Glenmark Pharmaceuticals Ltd
  - 13.4. Strides Pharma Science Ltd
  - 13.5. Ipca Laboratories Ltd
  - 13.6. Aurobindo Pharma Ltd
  - 13.7. Alkem Laboratories Ltd
  - 13.8. Novartis India Ltd
  - 13.9. Lupin Limited
  - 13.10. Cadila Healthcare Ltd
- 14. Strategic Recommendations
- 15. About Us & Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**India Antimalarial Drugs Market, By Drug Class (Aryl aminoalcohol compounds, Antifolate compounds, Artemisinin compounds, Others), By Mechanism of Action (Treatment for Malaria, Prevention from Malaria), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, Competition, Forecast & Opportunities, 2020-2030F**

Market Report | 2024-10-04 | 87 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-23"/>
		Signature	<input type="text"/>